IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Adenocarcinoma Breast Stage IV
Interventions: BIOLOGICAL: IMP321 (eftilagimod alpha)|DRUG: Placebo|DRUG: Paclitaxel
Sponsor: Immutep S.A.S.